RE:RE:Six months from now...I think the current situation is because of the unexplained delays in submitting the BTD application. There are probably very good reasons for the delays, but retail shareholders have no access to this kind of behind-the-scenes information. Longterm investors may be willing to trust that Theralase management is doing what needs to be done but there is no reason for the market in general to have this kind of faith in this admittedly risky venture. Theralase is pioneering the use of photodynamic therapy for bladder cancer and the last attempt to do this (in 1993 using photofrin as PS) was a disaster. Urologists still seem to be look askance at pdt for NMIBC all these years later as noted in the interview of Dr. Kulkarni by Dr. Kamat. The only real way up is definitive safety and efficacy results as evidenced by BTD, AA and full FDA approval.
Oilminerdeluxe wrote: But with these stellar numbers, we remain below 20 cents. What are we missing? There must be a reason or more.